# EDGAR Filing Document

**Accession Number:** 0001417663
**File Stem:** 0001628280-26-025553
**Filing Date:** 2026-4
**Character Count:** 9977
**Document Hash:** 7280bbf741937cbe47481a7373c608ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-025553.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001628280-26-025553

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260416

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SANUWAVE Health, Inc.
- **CENTRAL INDEX KEY:** 0001417663
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 201176000
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42552
- **FILM NUMBER:** 26868414

**BUSINESS ADDRESS:**
- **STREET 1:** 9600 W. 6TH SSTREET
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344
- **BUSINESS PHONE:** 952-656-1029

**MAIL ADDRESS:**
- **STREET 1:** 9600 W. 6TH SSTREET
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RUB MUSIC ENTERPRISES, INC.
- **DATE OF NAME CHANGE:** 20071106

?xml version='1.0' encoding='ASCII'? snwv-20260416

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

---

| | |
|:---|:---|
| Date of Report (Date of earliest event reported) | **April 16, 2026** |

---

---

| |
|:---|
| **SANUWAVE Health, Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-42552** | **20-1176000** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | | | |
|:---|:---|:---|:---|
| **9600 W. 76th Street, Suite 118,** | **Eden Prairie,** | **Minnesota** | **55344** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

---

| | | |
|:---|:---|:---|
| Registrant's telephone number, including area code | **(952)** | **656-1029** |

---

---

| |
|:---|
| **N/A** |
| (Former name or former address, if changed since last report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which**<br>**registered** |
| Common stock, par value $0.001 per share | SNWV | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results of Operations and Financial Condition.**

On April 16, 2026, Sanuwave Health, Inc., a Nevada corporation (the "Company"), issued a press release announcing certain preliminary financial results for the quarter ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits.**

(d)Exhibits.

---

| | |
|:---|:---|
| **Exhibit** <br>**No.** | **Description** |
| <u>[99.1](ex-991snwvpressreleasex416.htm)</u> | Press Release dated April 16, 2026 |
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | SANUWAVE HEALTH, INC. | SANUWAVE HEALTH, INC. |
| Dated: April 16, 2026 | By: | */s/ Peter Sorensen* |
|  | Name: | Peter Sorensen |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![logo.jpg](logo.jpg)

**Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6–$9.7 Million, Up 3-4% Year-over-Year**

*Sanuwave is pleased to announce preliminary revenues of $9.6 million to $9.7 million for the first quarter ended March 31, 2026, in line with prior guidance for Q1.*

EDEN PRAIRIE, MN, April 16, 2026 (GLOBE NEWSWIRE) Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the first quarter of 2026 are expected to be in the range of $9.6 to $9.7 million, an increase of 3-4% over Q1 2025. This number is within the range of guidance given in the Company's Q4 2025 earnings release issued on March 26, 2026.

"At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in toward the lower end of our guidance range," said CEO Morgan Frank. "Q1 has been a sort of reckoning in the wound care space as practitioners and customers came to terms with some significant changes in reimbursement for skin substitutes and allografts and this has caused many market participants and practitioners to pause or pull back from their activities in advanced wound care. But, as we discussed on our Q4 call, the patients and the wounds have not gone away and the need for care remains. At the SAWC conference in Charlotte last week, we spoke to a great many practitioners who were asking 'So what now?' and looking for options going forward. Our booth was as busy as any of us can ever recall seeing it, our hands-on workshops were full, and interest was high. For these reasons, we're not pulling back but rather leaning in as we believe that Ultramist can be an important part of the forward roadmap for patient care. I'm not sure we can quite say 'the tide has fully turned' at this point, but, at the very least, it does seem like perhaps the turn is starting and our optimism is increasing. We look forward to speaking with you further on this and providing some more color when we report our Q1 number in May."

The preliminary revenue results described herein are based on management's initial analysis of the first quarter ended March 31, 2026, and may be subject to adjustments based on the Company's completion of its quarter-end financial close process.

**About Sanuwave**

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

------

**Forward-Looking Statements**

*This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company's ability to manage its capital resources, competition and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.*

Contact: <u>investors@sanuwave.com</u>

<br>